Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial-Reference-Cited by-同舟云学术

Body fluid regulation via chronic inhibition of sodium–glucose cotransporter-2 in patients with heart failure: a post hoc analysis of the CANDLE trial

Published:2022-06-22 Issue:1 Volume:112 Page:87-97
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Fujiki Shinya^ORCID,Tanaka Atsushi,Imai Takumi,Shimabukuro Michio,Uehara Hiroki,Nakamura Ikuko,Matsunaga Kazuo,Suzuki Makoto,Kashimura Takeshi,Minamino Tohru,Inomata Takayuki,Node Koichi,

Funder

Mitsubishi Tanabe Pharma Corporation

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00392-022-02049-4.pdf

Reference33 articles.

1. Zelniker TA, Wiviott SD, Raz I et al (2019) SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 393:31–39. https://doi.org/10.1016/s0140-6736(18)32590-x

2. Zannad F, Ferreira JP, Pocock SJ et al (2020) SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials. Lancet 396:819–829. https://doi.org/10.1016/s0140-6736(20)31824-9

3. McMurray JJV, Solomon SD, Inzucchi SE et al (2019) Dapagliflozin in patients with heart failure and reduced ejection fraction. N Engl J Med 381:1995–2008. https://doi.org/10.1056/NEJMoa1911303